Bicalutamide 150 mg as secondary hormonal therapy for castration-resistant prostate cancer - Abstract

PURPOSE: PURPOSE:This study was aimed to evaluate the effect and tolerability of bicalutamide 150 mg therapy in patients with castration-resistant prostate cancer (CRPC).

METHODS: A total of 48 patients with histologically confirmed prostate cancer were included. They had been treated with continuous maximal androgen blockade therapy, but their serum prostate-specific antigen (PSA) increased after initial hormonal therapy. Patients were given bicalutamide (150 mg per day). Serum PSA testing was performed every 3 months. The response was defined according to PSA decline from baseline: PSA decline ≥85 % as complete response, ≥50 % but < 85 % as partial response, and < 50 % as failure. Response duration was defined as the time from PSA response until PSA increased ≥25 % or ≥2 ng/mL from the nadir. The potential predictive factors (Gleason score, clinical stage and serum PSA) were investigated.

RESULTS: The time of follow-up was 3-30 months. A PSA decline ≥50 % was observed in 37 of 48 patients including 18 ≥ 50 % but < 85 % and 19 ≥ 85 % responders. The median response duration was 12 months for partial responders and 20 months for complete responders. Patients with lower Gleason score, lower serum PSA and using flutamide as first-line nonsteroidal antiandrogen achieved more benefits. Moreover, bicalutamide 150 mg therapy was well tolerated.

CONCLUSIONS: Bicalutamide 150 mg therapy was an appropriate therapeutic method for patients of CRPC, especially for those with lower Gleason score, lower serum PSA and using flutamide as first-line nonsteroidal antiandrogen.

Written by:
Qian SB, Shen HB, Cao QF, Zhang L, Chen YF, Qi J.   Are you the author?
Department of Urology, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, 1665 Kongjiang Road, Yangpu District, Shanghai, 200092, China.

Reference: Int Urol Nephrol. 2015 Mar;47(3):479-84.
doi: 10.1007/s11255-015-0919-y

PubMed Abstract
PMID: 25665794 Prostate Cancer Section